XML 58 R47.htm IDEA: XBRL DOCUMENT v3.25.2
LICENSING AGREEMENTS AND ACQUISITIONS - Narrative (Details)
$ in Millions
1 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2025
USD ($)
therapy
Dec. 31, 2024
USD ($)
Dec. 31, 2025
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Business Combination [Line Items]              
Current portion included in Accrued and other current liabilities       $ 39   $ 39  
Goodwill   $ 11,087   11,298 $ 11,087   $ 11,183
DURECT | Bausch + Lomb | Forecast | Subsequent Event              
Business Combination [Line Items]              
Cash consideration paid     $ 63        
Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount     $ 350        
Business Combination, Contingent Consideration, Term     10 years        
Whitecap Biosciences Acquisition | Bausch + Lomb              
Business Combination [Line Items]              
Cash consideration paid $ 28     $ 28      
Number of innovative therapies | therapy 2            
Elios Vision | Bausch + Lomb              
Business Combination [Line Items]              
Cash consideration paid   99          
Business combination, contingent consideration, liability   89     89    
Current portion included in Accrued and other current liabilities   11     11    
Business combination consideration transferred         188    
Business combination, recognized asset acquired, identifiable intangible asset, excluding goodwill   177     177    
Business combination, recognized asset acquired, other asset, current   16     16    
Goodwill   $ 27     $ 27